APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis Vaccine Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Tuberculosis Vaccine Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025196 pages

Choose your research edition.

Industry ResearchTuberculosis Vaccine Drug Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis Vaccine Drug Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Tuberculosis Vaccine Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis Vaccine Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis Vaccine Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Tuberculosis Vaccine Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Tuberculosis Vaccine Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tuberculosis Vaccine Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tuberculosis Vaccine Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Tuberculosis Vaccine Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Tuberculosis Vaccine Drug include Merck, Taj Pharmaceuticals, Serum Institute of India, Queen Saovabha Mem. Inst, Microgen, Japan BCG Lab, IVAC, GreenSignal Bio Pharma and China National Biotec, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tuberculosis Vaccine Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tuberculosis Vaccine Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tuberculosis Vaccine Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tuberculosis Vaccine Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Tuberculosis Vaccine Drug Segment by Company

Merck

Taj Pharmaceuticals

Serum Institute of India

Queen Saovabha Mem. Inst

Microgen

Japan BCG Lab

IVAC

GreenSignal Bio Pharma

China National Biotec

Biomed Lublin

BioFarma

Ataulpho de Paiva

AJ Vaccines

Tuberculosis Vaccine Drug Segment by Type

Immune Vaccine

Therapy Vaccine

Tuberculosis Vaccine Drug Segment by Application

Self-Procurement

UNICEF

Other

Tuberculosis Vaccine Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccine Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccine Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccine Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tuberculosis Vaccine Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Tuberculosis Vaccine Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Tuberculosis Vaccine Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Tuberculosis Vaccine Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Tuberculosis Vaccine Drug Industry Trends Table 2. Tuberculosis Vaccine Drug Industry Drivers Table 3. Tuberculosis Vaccine Drug Industry Opportunities and Challenges Table 4. Tuberculosis Vaccine Drug Industry Restraints Table 5. Global Tuberculosis Vaccine Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Tuberculosis Vaccine Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Tuberculosis Vaccine Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Tuberculosis Vaccine Drug Sales Market Share by Manufacturers Table 9. Global Tuberculosis Vaccine Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Tuberculosis Vaccine Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Tuberculosis Vaccine Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Tuberculosis Vaccine Drug Manufacturers, Product Type & Application Table 13. Global Tuberculosis Vaccine Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Tuberculosis Vaccine Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Immune Vaccine Table 17. Major Manufacturers of Therapy Vaccine Table 18. Global Tuberculosis Vaccine Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Tuberculosis Vaccine Drug Sales by Type (2021-2026) & (k units) Table 20. Global Tuberculosis Vaccine Drug Sales by Type (2027-2032) & (k units) Table 21. Global Tuberculosis Vaccine Drug Sales Market Share by Type (2021-2026) Table 22. Global Tuberculosis Vaccine Drug Sales Market Share by Type (2027-2032) Table 23. Global Tuberculosis Vaccine Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Tuberculosis Vaccine Drug Revenue by Type (2021-2026) & (k units) Table 25. Global Tuberculosis Vaccine Drug Revenue by Type (2027-2032) & (k units) Table 26. Global Tuberculosis Vaccine Drug Revenue Market Share by Type (2021-2026) Table 27. Global Tuberculosis Vaccine Drug Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Self-Procurement Table 29. Major Manufacturers of UNICEF Table 30. Major Manufacturers of Other Table 31. Global Tuberculosis Vaccine Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Tuberculosis Vaccine Drug Sales by Application (2021-2026) & (k units) Table 33. Global Tuberculosis Vaccine Drug Sales by Application (2027-2032) & (k units) Table 34. Global Tuberculosis Vaccine Drug Sales Market Share by Application (2021-2026) Table 35. Global Tuberculosis Vaccine Drug Sales Market Share by Application (2027-2032) Table 36. Global Tuberculosis Vaccine Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Tuberculosis Vaccine Drug Revenue by Application (2021-2026) & (k units) Table 38. Global Tuberculosis Vaccine Drug Revenue by Application (2027-2032) & (k units) Table 39. Global Tuberculosis Vaccine Drug Revenue Market Share by Application (2021-2026) Table 40. Global Tuberculosis Vaccine Drug Revenue Market Share by Application (2027-2032) Table 41. Global Tuberculosis Vaccine Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Tuberculosis Vaccine Drug Sales by Region (2021-2026) & (k units) Table 43. Global Tuberculosis Vaccine Drug Sales Market Share by Region (2021-2026) Table 44. Global Tuberculosis Vaccine Drug Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Tuberculosis Vaccine Drug Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Tuberculosis Vaccine Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Tuberculosis Vaccine Drug Sales by Country (2021-2026) & (k units) Table 48. North America Tuberculosis Vaccine Drug Sales by Country (2027-2032) & (k units) Table 49. Europe Tuberculosis Vaccine Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Tuberculosis Vaccine Drug Sales by Country (2021-2026) & (k units) Table 51. Europe Tuberculosis Vaccine Drug Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Tuberculosis Vaccine Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Tuberculosis Vaccine Drug Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Tuberculosis Vaccine Drug Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Tuberculosis Vaccine Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Tuberculosis Vaccine Drug Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Tuberculosis Vaccine Drug Sales by Country (2027-2032) & (k units) Table 58. Global Tuberculosis Vaccine Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Tuberculosis Vaccine Drug Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Tuberculosis Vaccine Drug Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Tuberculosis Vaccine Drug Revenue Market Share by Region (2021-2026) Table 62. Global Tuberculosis Vaccine Drug Revenue Market Share by Region (2027-2032) Table 63. Merck Company Information Table 64. Merck Business Overview Table 65. Merck Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Merck Tuberculosis Vaccine Drug Product Portfolio Table 67. Merck Recent Development Table 68. Taj Pharmaceuticals Company Information Table 69. Taj Pharmaceuticals Business Overview Table 70. Taj Pharmaceuticals Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Taj Pharmaceuticals Tuberculosis Vaccine Drug Product Portfolio Table 72. Taj Pharmaceuticals Recent Development Table 73. Serum Institute of India Company Information Table 74. Serum Institute of India Business Overview Table 75. Serum Institute of India Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Serum Institute of India Tuberculosis Vaccine Drug Product Portfolio Table 77. Serum Institute of India Recent Development Table 78. Queen Saovabha Mem. Inst Company Information Table 79. Queen Saovabha Mem. Inst Business Overview Table 80. Queen Saovabha Mem. Inst Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Queen Saovabha Mem. Inst Tuberculosis Vaccine Drug Product Portfolio Table 82. Queen Saovabha Mem. Inst Recent Development Table 83. Microgen Company Information Table 84. Microgen Business Overview Table 85. Microgen Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Microgen Tuberculosis Vaccine Drug Product Portfolio Table 87. Microgen Recent Development Table 88. Japan BCG Lab Company Information Table 89. Japan BCG Lab Business Overview Table 90. Japan BCG Lab Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Japan BCG Lab Tuberculosis Vaccine Drug Product Portfolio Table 92. Japan BCG Lab Recent Development Table 93. IVAC Company Information Table 94. IVAC Business Overview Table 95. IVAC Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. IVAC Tuberculosis Vaccine Drug Product Portfolio Table 97. IVAC Recent Development Table 98. GreenSignal Bio Pharma Company Information Table 99. GreenSignal Bio Pharma Business Overview Table 100. GreenSignal Bio Pharma Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. GreenSignal Bio Pharma Tuberculosis Vaccine Drug Product Portfolio Table 102. GreenSignal Bio Pharma Recent Development Table 103. China National Biotec Company Information Table 104. China National Biotec Business Overview Table 105. China National Biotec Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. China National Biotec Tuberculosis Vaccine Drug Product Portfolio Table 107. China National Biotec Recent Development Table 108. Biomed Lublin Company Information Table 109. Biomed Lublin Business Overview Table 110. Biomed Lublin Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Biomed Lublin Tuberculosis Vaccine Drug Product Portfolio Table 112. Biomed Lublin Recent Development Table 113. BioFarma Company Information Table 114. BioFarma Business Overview Table 115. BioFarma Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. BioFarma Tuberculosis Vaccine Drug Product Portfolio Table 117. BioFarma Recent Development Table 118. Ataulpho de Paiva Company Information Table 119. Ataulpho de Paiva Business Overview Table 120. Ataulpho de Paiva Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Ataulpho de Paiva Tuberculosis Vaccine Drug Product Portfolio Table 122. Ataulpho de Paiva Recent Development Table 123. AJ Vaccines Company Information Table 124. AJ Vaccines Business Overview Table 125. AJ Vaccines Tuberculosis Vaccine Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. AJ Vaccines Tuberculosis Vaccine Drug Product Portfolio Table 127. AJ Vaccines Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Tuberculosis Vaccine Drug Distributors List Table 131. Tuberculosis Vaccine Drug Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Tuberculosis Vaccine Drug Product Image Figure 2. Global Tuberculosis Vaccine Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis Vaccine Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Tuberculosis Vaccine Drug Sales (2021-2032) & (k units) Figure 5. Global Tuberculosis Vaccine Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Tuberculosis Vaccine Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Immune Vaccine Image Figure 9. Therapy Vaccine Image Figure 10. Global Tuberculosis Vaccine Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Tuberculosis Vaccine Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Tuberculosis Vaccine Drug Sales Market Share by Type (2021-2032) Figure 13. Global Tuberculosis Vaccine Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Tuberculosis Vaccine Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Tuberculosis Vaccine Drug Revenue Market Share by Type (2021-2032) Figure 16. Self-Procurement Image Figure 17. UNICEF Image Figure 18. Other Image Figure 19. Global Tuberculosis Vaccine Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Tuberculosis Vaccine Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Tuberculosis Vaccine Drug Sales Market Share by Application (2021-2032) Figure 22. Global Tuberculosis Vaccine Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Tuberculosis Vaccine Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Tuberculosis Vaccine Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Tuberculosis Vaccine Drug Sales Market Share by Country (2021-2032) Figure 27. U.S. Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Tuberculosis Vaccine Drug Sales Market Share by Country (2021-2032) Figure 32. Germany Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Tuberculosis Vaccine Drug Sales Market Share by Country (2021-2032) Figure 39. China Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Tuberculosis Vaccine Drug Sales Market Share by Country (2021-2032) Figure 47. Brazil Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Tuberculosis Vaccine Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Tuberculosis Vaccine Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Tuberculosis Vaccine Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Tuberculosis Vaccine Drug Revenue (2021-2032) & (US$ Million) Figure 58. North America Tuberculosis Vaccine Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Tuberculosis Vaccine Drug Revenue (2021-2032) & (US$ Million) Figure 60. Europe Tuberculosis Vaccine Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Tuberculosis Vaccine Drug Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Tuberculosis Vaccine Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Tuberculosis Vaccine Drug Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Tuberculosis Vaccine Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Tuberculosis Vaccine Drug Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Tuberculosis Vaccine Drug Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Vaccine
  • Therapy Vaccine
Applications
  • Self-Procurement
  • UNICEF
  • Other
Companies covered
  • Merck
  • Taj Pharmaceuticals
  • Serum Institute of India
  • Queen Saovabha Mem. Inst
  • Microgen
  • Japan BCG Lab
  • IVAC
  • GreenSignal Bio Pharma
  • China National Biotec
  • Biomed Lublin
  • BioFarma
  • Ataulpho de Paiva
  • AJ Vaccines

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tuberculosis Vaccine Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tuberculosis Vaccine Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Tuberculosis Vaccine Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Tuberculosis Vaccine Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Tuberculosis Vaccine Drug Market Dynamics
  1. 2.1 Tuberculosis Vaccine Drug Industry Trends
  2. 2.2 Tuberculosis Vaccine Drug Industry Drivers
  3. 2.3 Tuberculosis Vaccine Drug Industry Opportunities and Challenges
  4. 2.4 Tuberculosis Vaccine Drug Industry Restraints
3 Tuberculosis Vaccine Drug Market by Manufacturers
  1. 3.1 Global Tuberculosis Vaccine Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Tuberculosis Vaccine Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Tuberculosis Vaccine Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Tuberculosis Vaccine Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Tuberculosis Vaccine Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Tuberculosis Vaccine Drug Manufacturers, Product Type & Application
  7. 3.7 Global Tuberculosis Vaccine Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Tuberculosis Vaccine Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Tuberculosis Vaccine Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Tuberculosis Vaccine Drug Tier 1, Tier 2, and Tier 3
4 Tuberculosis Vaccine Drug Market by Type
  1. 4.1 Tuberculosis Vaccine Drug Type Introduction
  2. 4.1.1 Immune Vaccine
  3. 4.1.2 Therapy Vaccine
  4. 4.2 Global Tuberculosis Vaccine Drug Sales by Type
  5. 4.2.1 Global Tuberculosis Vaccine Drug Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tuberculosis Vaccine Drug Sales by Type (2021-2032)
  7. 4.2.3 Global Tuberculosis Vaccine Drug Sales Market Share by Type (2021-2032)
  8. 4.3 Global Tuberculosis Vaccine Drug Revenue by Type
  9. 4.3.1 Global Tuberculosis Vaccine Drug Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tuberculosis Vaccine Drug Revenue by Type (2021-2032)
  11. 4.3.3 Global Tuberculosis Vaccine Drug Revenue Market Share by Type (2021-2032)
5 Tuberculosis Vaccine Drug Market by Application
  1. 5.1 Tuberculosis Vaccine Drug Application Introduction
  2. 5.1.1 Self-Procurement
  3. 5.1.2 UNICEF
  4. 5.1.3 Other
  5. 5.2 Global Tuberculosis Vaccine Drug Sales by Application
  6. 5.2.1 Global Tuberculosis Vaccine Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tuberculosis Vaccine Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Tuberculosis Vaccine Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Tuberculosis Vaccine Drug Revenue by Application
  10. 5.3.1 Global Tuberculosis Vaccine Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Tuberculosis Vaccine Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Tuberculosis Vaccine Drug Revenue Market Share by Application (2021-2032)
6 Global Tuberculosis Vaccine Drug Sales by Region
  1. 6.1 Global Tuberculosis Vaccine Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tuberculosis Vaccine Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Tuberculosis Vaccine Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Tuberculosis Vaccine Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tuberculosis Vaccine Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Tuberculosis Vaccine Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Tuberculosis Vaccine Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Tuberculosis Vaccine Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Tuberculosis Vaccine Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Tuberculosis Vaccine Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Tuberculosis Vaccine Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Tuberculosis Vaccine Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Tuberculosis Vaccine Drug Revenue by Region
  1. 7.1 Global Tuberculosis Vaccine Drug Revenue by Region
  2. 7.1.1 Global Tuberculosis Vaccine Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Tuberculosis Vaccine Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Tuberculosis Vaccine Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Tuberculosis Vaccine Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Tuberculosis Vaccine Drug Revenue (2021-2032)
  8. 7.2.2 North America Tuberculosis Vaccine Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Tuberculosis Vaccine Drug Revenue (2021-2032)
  11. 7.3.2 Europe Tuberculosis Vaccine Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Tuberculosis Vaccine Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Tuberculosis Vaccine Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Tuberculosis Vaccine Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Tuberculosis Vaccine Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Tuberculosis Vaccine Drug Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Taj Pharmaceuticals
  8. 8.2.1 Taj Pharmaceuticals Company Information
  9. 8.2.2 Taj Pharmaceuticals Business Overview
  10. 8.2.3 Taj Pharmaceuticals Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Taj Pharmaceuticals Tuberculosis Vaccine Drug Product Portfolio
  12. 8.2.5 Taj Pharmaceuticals Recent Developments
  13. 8.3 Serum Institute of India
  14. 8.3.1 Serum Institute of India Company Information
  15. 8.3.2 Serum Institute of India Business Overview
  16. 8.3.3 Serum Institute of India Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Serum Institute of India Tuberculosis Vaccine Drug Product Portfolio
  18. 8.3.5 Serum Institute of India Recent Developments
  19. 8.4 Queen Saovabha Mem. Inst
  20. 8.4.1 Queen Saovabha Mem. Inst Company Information
  21. 8.4.2 Queen Saovabha Mem. Inst Business Overview
  22. 8.4.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Drug Product Portfolio
  24. 8.4.5 Queen Saovabha Mem. Inst Recent Developments
  25. 8.5 Microgen
  26. 8.5.1 Microgen Company Information
  27. 8.5.2 Microgen Business Overview
  28. 8.5.3 Microgen Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Microgen Tuberculosis Vaccine Drug Product Portfolio
  30. 8.5.5 Microgen Recent Developments
  31. 8.6 Japan BCG Lab
  32. 8.6.1 Japan BCG Lab Company Information
  33. 8.6.2 Japan BCG Lab Business Overview
  34. 8.6.3 Japan BCG Lab Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Japan BCG Lab Tuberculosis Vaccine Drug Product Portfolio
  36. 8.6.5 Japan BCG Lab Recent Developments
  37. 8.7 IVAC
  38. 8.7.1 IVAC Company Information
  39. 8.7.2 IVAC Business Overview
  40. 8.7.3 IVAC Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 IVAC Tuberculosis Vaccine Drug Product Portfolio
  42. 8.7.5 IVAC Recent Developments
  43. 8.8 GreenSignal Bio Pharma
  44. 8.8.1 GreenSignal Bio Pharma Company Information
  45. 8.8.2 GreenSignal Bio Pharma Business Overview
  46. 8.8.3 GreenSignal Bio Pharma Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GreenSignal Bio Pharma Tuberculosis Vaccine Drug Product Portfolio
  48. 8.8.5 GreenSignal Bio Pharma Recent Developments
  49. 8.9 China National Biotec
  50. 8.9.1 China National Biotec Company Information
  51. 8.9.2 China National Biotec Business Overview
  52. 8.9.3 China National Biotec Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 China National Biotec Tuberculosis Vaccine Drug Product Portfolio
  54. 8.9.5 China National Biotec Recent Developments
  55. 8.10 Biomed Lublin
  56. 8.10.1 Biomed Lublin Company Information
  57. 8.10.2 Biomed Lublin Business Overview
  58. 8.10.3 Biomed Lublin Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biomed Lublin Tuberculosis Vaccine Drug Product Portfolio
  60. 8.10.5 Biomed Lublin Recent Developments
  61. 8.11 BioFarma
  62. 8.11.1 BioFarma Company Information
  63. 8.11.2 BioFarma Business Overview
  64. 8.11.3 BioFarma Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BioFarma Tuberculosis Vaccine Drug Product Portfolio
  66. 8.11.5 BioFarma Recent Developments
  67. 8.12 Ataulpho de Paiva
  68. 8.12.1 Ataulpho de Paiva Company Information
  69. 8.12.2 Ataulpho de Paiva Business Overview
  70. 8.12.3 Ataulpho de Paiva Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Ataulpho de Paiva Tuberculosis Vaccine Drug Product Portfolio
  72. 8.12.5 Ataulpho de Paiva Recent Developments
  73. 8.13 AJ Vaccines
  74. 8.13.1 AJ Vaccines Company Information
  75. 8.13.2 AJ Vaccines Business Overview
  76. 8.13.3 AJ Vaccines Tuberculosis Vaccine Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AJ Vaccines Tuberculosis Vaccine Drug Product Portfolio
  78. 8.13.5 AJ Vaccines Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tuberculosis Vaccine Drug Value Chain Analysis
  2. 9.1.1 Tuberculosis Vaccine Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tuberculosis Vaccine Drug Production Mode & Process
  6. 9.2 Tuberculosis Vaccine Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tuberculosis Vaccine Drug Distributors
  9. 9.2.3 Tuberculosis Vaccine Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst